Similar articles for PMID: 35440506

Year	Number of Results
2000	1
2010	1
2011	1
2012	1
2014	5
2015	7
2016	8
2017	15
2018	19
2019	20
2020	17
2021	12
2022	7
2024	0

1

Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data.

McClean AR, Law MR, Harrison M, Bansback N, Gomes T, Tadrous M. McClean AR, et al. CMAJ. 2022 Apr 19;194(15):E556-E560. doi: 10.1503/cmaj.211478. CMAJ. 2022. PMID: 35440506 Free PMC article. No abstract available.

2

Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.

Crosby M, Tadrous M, Gomes T. Crosby M, et al. Clin Pharmacol Ther. 2021 Mar;109(3):739-745. doi: 10.1002/cpt.2042. Epub 2020 Oct 3. Clin Pharmacol Ther. 2021. PMID: 32909249

3

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, Yang YT, Kommalapati A, Tella SH, DeAngelis C, Raisch DW, Sartor O, Hrushesky WJ, Ray PS, Yarnold PR, Love BL, Norris LB, Knopf K, Bobolts L, Riente J, Luminari S, Kane RC, Hoque S, Bennett CL. Chen B, et al. Oncologist. 2019 Apr;24(4):537-548. doi: 10.1634/theoncologist.2018-0341. Epub 2019 Mar 6. Oncologist. 2019. PMID: 30842244 Free PMC article.

4

Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis.

Gomes T, McCormack D, Kitchen SA, Paterson JM, Mamdani MM, Proulx L, Bayliss L, Tadrous M. Gomes T, et al. CMAJ Open. 2021 Nov 23;9(4):E1055-E1062. doi: 10.9778/cmajo.20210091. Print 2021 Oct-Dec. CMAJ Open. 2021. PMID: 34815261 Free PMC article.

5

Postmarket policy considerations for biosimilar oncology drugs.

Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Renwick MJ, et al. Lancet Oncol. 2016 Jan;17(1):e31-8. doi: 10.1016/S1470-2045(15)00381-2. Epub 2015 Dec 23. Lancet Oncol. 2016. PMID: 26758759 Review.

6

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Moorkens E, et al. BioDrugs. 2019 Jun;33(3):299-306. doi: 10.1007/s40259-019-00346-5. BioDrugs. 2019. PMID: 30945206 Free PMC article.

7

Biosimilar drugs: Measures to promote their use.

Guiu Segura JM, Gilabert Perramon A. Guiu Segura JM, et al. Med Clin (Barc). 2020 Feb 28;154(4):148. doi: 10.1016/j.medcli.2019.02.013. Epub 2019 Apr 10. Med Clin (Barc). 2020. PMID: 30981435 English, Spanish. No abstract available.

8

Greater potential cost savings with biosimilar use.

Yu B. Yu B. Am J Manag Care. 2016 May;22(5):378. Am J Manag Care. 2016. PMID: 27266439 Free article. No abstract available.

9

Friction in the Path to Use of Biosimilar Drugs.

Frank RG. Frank RG. N Engl J Med. 2018 Mar 1;378(9):791-793. doi: 10.1056/NEJMp1714908. N Engl J Med. 2018. PMID: 29490182 No abstract available.

10

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review.

Hillhouse E, Mathurin K, Bibeau J, Parison D, Rahal Y, Lachaine J, Beauchemin C. Hillhouse E, et al. Adv Ther. 2022 Jan;39(1):455-487. doi: 10.1007/s12325-021-01951-z. Epub 2021 Nov 15. Adv Ther. 2022. PMID: 34780028 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

98 results

Results by year